Arkansas Doc Loses Prescription Power in DEA Smackdown
Published Date: 1/27/2026
Notice
Summary
Dr. Adam Maass from Arkansas lost his DEA registration because he can’t legally handle controlled substances in his state anymore. He didn’t ask for a hearing, so the DEA canceled his registration by default. This means he must stop prescribing or handling controlled drugs immediately, affecting his medical practice and any related income.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
DEA Registration Revoked; Renewals Denied
The DEA revoked Adam Maass, M.D.'s Certificate of Registration No. BM6528369 and denied any pending applications to renew, modify, or add registration in Arkansas. The Order follows his March 5, 2025 guilty plea, his April 25, 2025 surrender of his Arkansas medical license (currently listed as "Inactive"), and his failure to request a hearing; the Order is effective "[insert Date Thirty Days From the Date of Publication in the Federal Register]."
15-Day Right To Seek Reconsideration
The Agency took official notice that Dr. Maass's Arkansas medical license is "Inactive," and the Order states he may file a properly supported motion for reconsideration of the findings of fact within fifteen calendar days of the date of the Order. Any such motion and response must be filed and served by email, including to the DEA Office of the Administrator at [email protected].
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2026-01498 — Complete Care Pharmacy, LLC; Decision and Order
Complete Care Pharmacy in New Mexico lost its DEA license because its owner filled 26 drug prescriptions without having the legal authority to do so. This means the pharmacy can no longer handle controlled substances, impacting its business immediately. Anyone relying on this pharmacy for such medications will need to find a new provider fast.
Next: 2026-01500 — Arms Sales Notification
The U.S. Department of Defense is updating Congress about a big arms sale to Australia, including 29 Apache attack helicopters and lots of high-tech gear and missiles. This deal, first notified in 2021, involves advanced upgrades to make the equipment even better. It’s a major move that keeps Australia’s defense strong and shows ongoing U.S. support with cutting-edge military tech.